---
title: "VASTDATA: Net profit loss of 44.7074 million yuan in the first half of 2025"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/253773686.md"
description: "VASTDATA announced that its operating revenue in the first half of 2025 was 232 million yuan, a year-on-year increase of 13.98%. The net profit attributable to shareholders of the listed company was -44.7074 million yuan, compared to -24.1191 million yuan in the same period last year. The basic earnings per share were -0.152 yuan/share"
datetime: "2025-08-20T09:02:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/253773686.md)
  - [en](https://longbridge.com/en/news/253773686.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/253773686.md)
generator: "portal-rs"
---

# VASTDATA: Net profit loss of 44.7074 million yuan in the first half of 2025

VASTDATA announced that its operating revenue in the first half of 2025 was 232 million yuan, a year-on-year increase of 13.98%. The net profit attributable to shareholders of the listed company was -44.7074 million yuan, compared to -24.1191 million yuan in the same period last year. The basic earnings per share were -0.152 yuan/share

### Related Stocks

- [603138.CN](https://longbridge.com/en/quote/603138.CN.md)

## Related News & Research

- [PostgreSQL 19 connects the dots with standardized graph queries](https://longbridge.com/en/news/298043695.md)
- [Mabwell reports Phase Ib/IIa data showing anti-ST2 antibody 9MW1911 cuts COPD exacerbations up to 81%](https://longbridge.com/en/news/298042457.md)
- [ENAV COO Maurizio Paggetti sells 10,000 ordinary shares for EUR 50,330 via closely associated person](https://longbridge.com/en/news/297764675.md)
- [12:09 ETHaier Biomedical präsentiert automatisierte Biolagerung und vernetzte Pharma-Lösungen auf der ISPE Singapore 2026](https://longbridge.com/en/news/297810393.md)
- [Biocytogen and Qilu Pharmaceutical sign agreement for VHH antibody molecule](https://longbridge.com/en/news/297892535.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**